Arizona Clinical Trials | Chandler, AZ

Research site

(Unclaimed)

Location

910 East Pecos Road, Chandler, Arizona, United States of America

Site insights

Top conditions

Top treatments

Maridebart Cafraglutide

MK-1084

Vorasidenib

CRB-913

MK-8527-015

Pasritamig

Docetaxel

BMS-986435

MK-8527

BI 1584862

Parent organization

This site is a part of Arizona Clinical Trials

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 10 total trials

A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity (CANYON-1)

This study will assess the safety of the investigational drug CRB-913 and how it is processed in the body.The study has two parts: Part 1 will measur...

Active, not recruiting

Obese But Otherwise Healthy Participants

Drug: CRB-913

Drug: Placebo

A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)

The purpose of this study is to learn what happens to calderasib levels in a person's body over time. Researchers will measure what happens to calder...

Enrolling

Hepatic Impairment

Healthy

Drug: Calderasib

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (KLK2-PASenger)

The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the...

Enrolling

Prostatic Neoplasms, Castration-Resistant

Drug: Docetaxel

Drug: Prednisone

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

The purpose of this study is to determine the pharmacokinetic and safety of BMS-986435 in participants with normal hepatic function and participants...

Enrolling

Hepatic Impairment

Healthy Volunteers

Drug: BMS-986435

A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight

The main objective of this trial will be to determine whether maridebart cafraglutide is superior to placebo on reduction in liver fat content and bo...

Enrolling

Overweight or Obesity and Elevated Liver Fat

Drug: Placebo

Drug: Maridebart cafraglutide

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

Enrolling

Obesity or Overweight

Drug: Maridebart Cafraglutide

Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants

The objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of one dose of vorasidenib in participants with severe impa...

Enrolling

Severe Hepatic Impairment

Normal Hepatic Function

Drug: Vorasidenib 20mg

ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG

This is a phase 1/2, open-label, multicenter study of intravesical Recombinant Mycobacterium Bacillus Calmette-Guérin (BCG) in participants with Non-...

Enrolling

NMIBC

Biological: Intravesical Recombinant Mycobacterium (rMBCG)